Stay updated on MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page.

Latest updates to the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.3.2 is now shown on the page, replacing Revision: v3.2.0, an internal version/update label with no changes to study details or eligibility information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedThe funding/operating status notice was removed. Core study details including the title, NCT number, locations, and eligibility criteria remain unchanged.SummaryDifference0.3%

- Check34 days agoChange DetectedThe screenshots show the same study record with no core information changes; only formatting/layout variations are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check63 days agoChange DetectedAdded new operating-status notices, 18 new Local Institution entries, and a 2025-09 update with revision v3.2.0; removed numerous previously listed sites and detailed contacts, including several locations marked as Recruiting or Withdrawn. Overall: more updated status and expanded/altered site list, with several sites removed.SummaryDifference21%

- Check70 days agoChange DetectedAdded numerous phone numbers, a medical term (Colonic Neoplasms), and a software revision tag v3.1.0; removed the older revision tag v3.0.2.SummaryDifference0.2%

- Check84 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, and the 'Back to Top' element has been removed.SummaryDifference0.2%

Stay in the know with updates to MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MRTX0902 for KRAS Mutation Solid Tumors Clinical Trial page.